Equities research analysts expect that ICU Medical, Inc. (NASDAQ:ICUI) will report earnings per share of $0.58 for the current quarter, according to Zacks Investment Research. Two analysts have made estimates for ICU Medical’s earnings, with the lowest EPS estimate coming in at $0.52 and the highest estimate coming in at $0.64. ICU Medical reported earnings of $0.98 per share in the same quarter last year, which suggests a negative year over year growth rate of 40.8%. The business is scheduled to announce its next quarterly earnings report on Monday, August 14th.
According to Zacks, analysts expect that ICU Medical will report full year earnings of $3.43 per share for the current financial year, with EPS estimates ranging from $3.27 to $3.72. For the next financial year, analysts expect that the company will post earnings of $5.41 per share, with EPS estimates ranging from $5.36 to $5.47. Zacks’ EPS calculations are a mean average based on a survey of sell-side analysts that cover ICU Medical.
ICU Medical (NASDAQ:ICUI) last issued its earnings results on Wednesday, May 10th. The medical instruments supplier reported $1.68 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.45 by $1.23. The firm had revenue of $247.74 million for the quarter, compared to the consensus estimate of $237.12 million. ICU Medical had a net margin of 18.76% and a return on equity of 9.63%. The business’s revenue was up 175.7% on a year-over-year basis. During the same quarter in the prior year, the firm posted $1.26 earnings per share.
ICUI has been the subject of several analyst reports. Zacks Investment Research cut shares of ICU Medical from a “buy” rating to a “hold” rating in a research note on Monday, March 13th. Roth Capital cut shares of ICU Medical from a “buy” rating to a “neutral” rating in a research note on Thursday, May 11th. They noted that the move was a valuation call. Finally, BidaskClub upgraded shares of ICU Medical from a “hold” rating to a “buy” rating in a research note on Saturday.
In other ICU Medical news, VP Alison D. Burcar sold 18,290 shares of the company’s stock in a transaction on Wednesday, May 17th. The shares were sold at an average price of $160.72, for a total transaction of $2,939,568.80. Following the completion of the transaction, the vice president now directly owns 3,727 shares in the company, valued at $599,003.44. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Robert S. Swinney sold 594 shares of the company’s stock in a transaction on Wednesday, May 17th. The stock was sold at an average price of $160.92, for a total transaction of $95,586.48. Following the transaction, the director now owns 14,793 shares of the company’s stock, valued at $2,380,489.56. The disclosure for this sale can be found here. Insiders have sold 23,384 shares of company stock valued at $3,766,450 over the last 90 days. 15.90% of the stock is currently owned by company insiders.
A number of institutional investors have recently bought and sold shares of ICUI. BlackRock Inc. boosted its position in ICU Medical by 87,088.7% in the first quarter. BlackRock Inc. now owns 1,769,930 shares of the medical instruments supplier’s stock worth $270,268,000 after buying an additional 1,767,900 shares in the last quarter. Janus Capital Management LLC boosted its position in ICU Medical by 178.8% in the first quarter. Janus Capital Management LLC now owns 1,439,864 shares of the medical instruments supplier’s stock worth $219,864,000 after buying an additional 923,395 shares in the last quarter. Redmile Group LLC bought a new position in ICU Medical during the first quarter worth $24,515,000. Norges Bank bought a new position in ICU Medical during the fourth quarter worth $18,127,000. Finally, Wells Fargo & Company MN boosted its position in ICU Medical by 29.3% in the first quarter. Wells Fargo & Company MN now owns 465,840 shares of the medical instruments supplier’s stock worth $71,133,000 after buying an additional 105,570 shares in the last quarter. Institutional investors own 77.95% of the company’s stock.
Shares of ICU Medical (NASDAQ ICUI) traded up 1.95% on Monday, hitting $172.10. 116,694 shares of the stock traded hands. The stock has a market cap of $3.41 billion, a P/E ratio of 30.59 and a beta of 0.38. ICU Medical has a 52-week low of $102.05 and a 52-week high of $175.73. The stock’s 50 day moving average price is $162.41 and its 200 day moving average price is $151.02.
About ICU Medical
ICU Medical, Inc is engaged in the development, manufacture and sales of medical devices used in infusion therapy, oncology and critical care applications. The Company’s product line includes needlefree connection devices, custom infusion sets, closed system transfer devices (CSTD) for the handling of hazardous drugs, advanced sensor catheters, needlefree closed blood sampling systems, disposable pressure transducer systems and hemodynamic monitoring systems.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ICU Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ICU Medical Inc. and related companies with our FREE daily email newsletter.